Validation of the 18 kiloDalton Translocator Protein (TSPO) as a Novel Neuroimmunodulatory Target
NCT03850301
·
clinicaltrials.gov ↗
NA
Phase
RECRUITING
Status
44
Enrollment
OTHER
Sponsor class
Conditions
Multiple Sclerosis
Interventions
DRUG:
XBD173
DRUG:
Etifoxine
Sponsor
Imperial College London